Haishan is CEO of Panorama Medicine, an early stage drug developer focusing on AI-assisted RNA splicing. Using this innovative discovery engine, Panorama has established a diverse portfolio. Before joining Panorama, Haishan was VP of Alliance at LianBio (NASDAQ: LIAN), leading regulatory and clinical implementation of the company’s diverse pipeline. Haishan obtained broad experience in drug development as CBO of KBP BioSciences (a clinical stage biotech) and SVP of ClinChoice (formerly FMD, a clinical CRO). Before moving into drug development, Haishan spent 12 years in drug commercialization at Roche and Spectrum Pharma. Haishan holds a BS in Bioengineering from Nankai University, a PhD in Biochemistry from Penn State University, and MBA from The Wharton School University of Pennsylvania.